Home/IGC Pharma/Claudia Grimaldi

CG

Claudia Grimaldi

VP, CCO, PFO, & Director

Therapeutic Areas

Alzheimer's Disease Central Nervous System Disorders

IGC Pharma Pipeline

Drug	Indication	Phase
IGC-AD1	Agitation in Alzheimer's Dementia	Phase 2
TGR-63	Early-Moderate Stage Alzheimer's (Aβ Plaques)	Preclinical
IGC-1C	Alzheimer's (Tau pathology)	Preclinical
IGC-M3	Alzheimer's (Aβ Plaques aggregation)	Preclinical
IGC-LMP	Alzheimer's Agitation Symptoms (Neuroinflammation)	Preclinical

Leadership Team at IGC Pharma

Chairman of the Board

Prof. Pablo Arbeláez

Prof. Chuanhai Cao, Ph.D.

Advisor (Pharmaceutical Sciences)

Prof. Elliot L. Hong

Advisor (Psychiatry)

Prof. Joseph Fortunak, Ph.D.

Advisor (Chemistry & Pharmaceutical Sciences)

Prof. T. Govindaraju, Ph.D, FRSC

Advisor (Bioorganic Chemistry)

View full IGC Pharma profile